The Day In Review: News On Multiple Sclerosis Drugs

September 28, 2006 -- Novartis said FTY720 prevented relapse in 77% of MS patients; Serono released positive data from an improved formulation of Rebif; Biogen Idec and Elan reported Tysabri helped prevent loss of cognitive function in MS; GlaxoSmithKline licensed the avian flu treatment Relenza to a Chinese company; Threshold received orphan drug status for cancer drug glufosfamide; Sangamo hopes its zinc finger drugs make cells resistant to HIV; Discovery Labs says it has solved the stabilization problems in Surfaxin; Sonus will begin a Phase I study of its second cancer drug; and Alnylam won a $23 million grant to develop anti-viral drugs. The Centient Biotech 200™ fell two points to 3821.10, a loss of .04%. More details...